Skip to content

Author

Eriko Yamamoto

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Enhanced liver injury and fibrosis markers after anti-PD-1 treatment in an HFD/CCl4-accelerated MASH-fibrosis mouse model

Immune checkpoint inhibitors show variable efficacy in hepatocellular carcinoma depending on etiology. In metabolic dysfunction-associated steatohepatitis (MASH), PD-1+ CD8+ T cells may paradoxically drive liver injury. We investigated whether PD-1 blockade exacerbates liver fibrosis in a non-neoplastic MASH environm...

Panuwat Promsorn, Takashi Yamaguchi, Eriko Yamamoto et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.